BioCentury | May 8, 2020
Regulation

$8B Loxo deal yields first drug with approval of Lilly’s targeted lung cancer therapy

FDA’s approval of Retevmo selpercatinib from Eli Lilly is the second approval for a genetically defined subset of non-small cell lung cancer patients this week. The selective RET inhibitor is the first product of the...
BC Week In Review | Sep 1, 2017
Company News

NICE issues draft guidance against Cometriq and Caprelsa

NICE issued draft guidance recommending against the use of two drugs to treat medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease. The committee said clinical trial evidence showed Cometriq cabozantinib from...
BC Innovations | Mar 9, 2017
Translation in Brief

To screen and protect

A Science Translational Medicine study has established a quantitative metric of drug cardiotoxicity in human-derived cardiomyocytes, and identified insulin-based strategies to alleviate the cardiotoxicity of certain tyrosine kinase inhibitors (TKIs). Study leader Joseph Wu said...
BC Week In Review | Dec 9, 2016
Clinical News

Caprelsa regulatory update

EMA’s CHMP recommended expanding the label of Caprelsa vandetanib from Sanofi to treat aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease to include children and adolescents ages...
BC Week In Review | Sep 14, 2015
Company News

Sanofi, AstraZeneca deal

Sanofi’s Genzyme Corp. unit will purchase Caprelsa vandetanib from AstraZeneca for $165 million up front and up to $135 million in development and sales milestones. The EGFR and VEGF receptor kinase inhibitor approved in the...
BC Week In Review | Jun 1, 2015
Clinical News

Caprelsa vandetanib: Phase I data

Data from 41 patients with solid tumors in an open-label, dose-escalation, UK Phase I trial showed that once-daily oral vandetanib plus oral selumetinib led to 4 cases of stable disease in patients with non-small cell...
BC Week In Review | Jun 1, 2015
Clinical News

Selumetinib: Phase I data

Data from 41 patients with solid tumors in an open-label, dose-escalation, UK Phase I trial showed that once-daily oral vandetanib plus oral selumetinib led to 4 cases of stable disease in patients with non-small cell...
BC Innovations | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Fumarate hydratase (FH); v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1)

Cancer INDICATION: Renal cancer Cell culture and mouse studies suggest ABL1 inhibitors could help treat FH-deficient renal cancers. In FH-deficient hereditary leiomyomatosis and renal cell carcinoma (HLRCC) cell cultures, the ABL1 inhibitor vandetanib or an...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BC Week In Review | Sep 9, 2013
Clinical News

Caprelsa vandetanib regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Caprelsa vandetanib from AstraZeneca has "marginal" additional benefit over best supportive care for aggressive, symptomatic medullary thyroid cancer (MTC) that is unresectable, locally...
Items per page:
1 - 10 of 108